glp 1 agonist perioperative Glucagon-Like Peptide-1 Receptor Agonists in Care Are GLP-1 medications helping—or complicating—surgical

Modifiable risk factors driving knee OA development include: Obesity it is estimated that every 5 kg (10 lb) of body weight increases knee OA risk by up to 35%

Visible body composition changes are unlikely at this stage, but the internal fat-mobilisation process has begun

The batterys internal resistance 3 also plays a role here

W.MaoX.PillemerS.DykeJ

NICE Technology Appraisal 875 (Wegovy) and TA664 (Saxenda) recommend these treatments within specialist tier 3 or 4 weight management services for adults with a BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds), with weight-related comorbidities